Galapagos NV (NASDAQ:GLPG) has been given a consensus recommendation of “Buy” by the eleven ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $101.00.
Several equities research analysts have recently commented on GLPG shares. BTIG Research reissued a “buy” rating and set a $98.00 target price on shares of Galapagos NV in a research report on Wednesday, July 26th. Zacks Investment Research upgraded shares of Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a research note on Friday, July 14th. Instinet reiterated a “buy” rating and issued a $108.00 target price (down from $121.00) on shares of Galapagos NV in a research note on Thursday, June 22nd. Nomura dropped their target price on shares of Galapagos NV from $108.00 to $121.00 and set a “buy” rating on the stock in a research note on Thursday, June 22nd. Finally, Cowen and Company restated a “buy” rating on shares of Galapagos NV in a research note on Wednesday, June 21st.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by BNB Daily and is the property of of BNB Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/galapagos-nv-glpg-receives-average-recommendation-of-buy-from-analysts-updated-updated-updated.html.
Galapagos NV (NASDAQ GLPG) traded up 3.28% during midday trading on Monday, reaching $83.72. The company had a trading volume of 160,092 shares. Galapagos NV has a 12 month low of $52.50 and a 12 month high of $94.88. The firm’s market capitalization is $4.26 billion. The firm’s 50-day moving average price is $77.64 and its 200 day moving average price is $79.02.
A number of hedge funds have recently bought and sold shares of GLPG. Bogle Investment Management L P DE purchased a new stake in Galapagos NV during the first quarter valued at about $368,000. Airain ltd bought a new position in shares of Galapagos NV during the first quarter worth approximately $237,000. Wellington Management Group LLP raised its position in shares of Galapagos NV by 9.5% in the first quarter. Wellington Management Group LLP now owns 458,088 shares of the biotechnology company’s stock worth $39,483,000 after buying an additional 39,729 shares during the last quarter. Bank of Montreal Can raised its position in shares of Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock worth $168,000 after buying an additional 1,922 shares during the last quarter. Finally, Driehaus Capital Management LLC bought a new position in shares of Galapagos NV during the first quarter worth approximately $942,000. Institutional investors and hedge funds own 19.99% of the company’s stock.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.